High prevalence of <it>dhfr </it>triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures <it>in vivo </it>in Gabonese children
Profanter Katharina, Greutélaers Katja C, Gabor Julian J and 11 more
Malaria Journal · 2011
doi:10.1186/1475-2875-10-123 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>Drug resistance contributes to the global malaria burden. <it>Plasmodium </it><it>falciparum </it>dihydrofolate reductase (<it>dhfr</it>) and dihydropteroate synthase (<it>dhps</it>) polymorphisms confer resistance to sulphadoxine-pyrimethamine (SP).</p> <p>Methods</p> <p>The study assessed the frequency of SP resistance-conferring polymorphisms in <it>Plasmodium </it><it>falciparum</it>-positive samples from two clinical studies in Lambaréné. Their role on treatment responses and transmission potential was studied in an efficacy open-label clinical trial with a 28-day follow-up in 29 children under five with uncomplicated malaria.</p> <p>Results</p> <p>SP was well tolerated by all subjects in vivo. Three subjects were excluded from per-protocol analysis. PCR-corrected, 12/26 (46%) achieved an adequate clinical and parasitological response, 13/26 (50%) were late parasitological failures, while 1/26 (4%) had an early treatment failure, resulting in early trial discontinuation. Of 106 isolates, 98 (92%) carried the triple mutant <it>dhfr </it>haplotype. Three point mutations were found in <it>dhps </it>in a variety of haplotypic configurations. The 437G + 540E double mutant allele was found for the first time in Gabon.</p> <p>Conclusions</p> <p>There is a high prevalence of <it>dhfr </it>triple mutant with some <it>dhps </it>point mutations in Gabon, in line with treatment failures observed, and molecular markers of SP resistance should be closely monitored.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00453856">NCT00453856</a></p>
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.